Track the 바이오노트 stock price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares are listed on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 바이오노트 has logged 31 reports. Market capitalisation: €490.7bn. The latest transaction was reported on 29 May 2026 (Purchase). Among the most active insiders: 조영식. The full history is openly available.
31
Insider Decl.
0
Thresholds
€1m
10 ops.
Buy Volume
·
0 ops.
Sell Volume
32Σ signal
Buys €1m· Sells
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 20,229 of 25,535 companies
31.2
score / 100
Value
29
Quality
33
FCF yld1.3%
Earn yld-19%
EV/EBITDA·
ROE-3.2%
Gross mgn56%
Net mgn-74%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
